Grail (GRAL) Stock News: September 2026
$GRAL · 4 stories in September 2026September 2026
newest first · direct subject stories onlyFDA Panel Discusses Grail's Cancer Blood Test Galleri
FDA advisory committee meets on Grail's Galleri blood test for multi-cancer early detection. Approval would unlock Medicare and insurance reimbursement, but the test's landmark study missed its goal in June. Analysts expect a constrained label. Panel vote due Wednesday.
bullish 65 · impact 40FDA advisors back Grail's cancer-finding blood test
FDA advisors back Grail's cancer-finding blood test.
bullish 65 · impact 70FDA panel weighs Grail blood test Galleri for cancer screening
FDA panel discussed Grail's Galleri blood test for cancer screening, focusing on labeling concerns. Grail stock halted. Analysts see path to approval but cite commercialization hurdles.